Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development

Merck KGaA has withdrawn its EU marketing application for a lung cancer indication for its cancer drug Erbitux after regulatory authorities requested more clinical data. The company will no longer pursue a non-small cell lung cancer (NSCLC) indication, spokeswoman Phyllis Carter said.
Drug Industry Daily